Izotropic Corp. IZOZF Archives

FridayOct 24, 2025 11:40 am

QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in NetworkNewsWire Editorial on AI-Driven Breast Cancer Imaging

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market.” The publication explores how artificial intelligence (AI) is reshaping medical imaging, particularly in breast cancer detection, where early and precise diagnosis remains critical to survival rates. Izotropic is highlighted for its IzoView Breast CT Imaging System, a 3D imaging technology designed to improve detection accuracy in women with dense breast tissue. The company’s innovation aligns with rising global demand for advanced diagnostic solutions, as breast cancer remains the most frequently diagnosed cancer among women…

WednesdayOct 22, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Breast Cancer Awareness Month by Addressing Gaps in Screening and Advancing the IzoView Breast CT Solution

Izotropic highlights recurrent challenges in current breast imaging technologies and the need for high-resolution, true 3D imaging The IzoView breast CT scan technology is created for accurate, compression-free imaging for women who have dense breast tissue Increased screening demands and regulatory momentum underscore the opportunities for dedicated breast CT solutions IZOZF's innovative approaches highlight the company's mission to improve diagnosis, detection, and care for people globally Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device firm leading imaging-based solutions for better diagnosis, screening, and treatment of breast cancer patients, is bringing the challenges of current screening systems and the…

FridayOct 17, 2025 2:52 pm

QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Unveils IzoView: A Game-Changing Platform for Next-Gen Breast Cancer Detection

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is leading a transformation in breast cancer screening with its flagship IzoView Breast CT Imaging System, a next-generation technology designed to overcome the long-standing limitations of traditional mammography. Unlike compression-based 2D imaging, IzoView delivers true 360-degree, 3D visualization without discomfort, enabling clearer detection—especially in dense breast tissue, which often obscures lesions in standard scans. With a rapid 10-second scan time, high spatial resolution surpassing MRI, and radiation levels comparable to conventional mammography, the system streamlines diagnosis while enhancing patient safety and experience. Built as a scalable platform, IzoView supports future software-driven clinical applications—from screening…

WednesdayOct 15, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Advances AI-Powered Breast CT Innovation and Reinforces Its Commitment to Safer, Smarter Cancer Imaging

Izotropic recently published a piece that explores the way AI is redefining breast imaging and the way the innovative IzoView system was designed for the future The company's 3D breast CT platform helps tackle one of the major concerns of cancer screening: radiation exposure in CT imaging With its trade-secret reconstruction algorithm, AI-native design, and fair price model, IzoView strategically places Izotropic to dominate the future of breast imaging technology These latest updates further highlight Izotropic's mission: to redefine breast diagnostics using innovation that prioritizes safety, precision, and accessibility Izotropic (CSE: IZO) (OTCQB: IZOZF) is changing how breast cancer imaging…

WednesdayOct 08, 2025 11:15 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Expands Commercialization Strategy with $375K Financing, Investor Awareness Agreements, and Breakthrough Personalized Radiation Dose Breast CT

Izotropic Corp. marks a significant milestone in breast imaging with its patent-pending personalized radiation dose feature with the IzoView Breast CT system Recently, the company secured a $375,000 non-brokered private placement to help with core operations in addition to engaging new PR partners for improved investor communications With projections for global breast imaging expected to hit $8.69 billion by 2030, the company is poised to strategically dominate the market Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a leading medical device firm in the field of breast cancer imaging solutions, is speeding up its efforts towards commercializing its innovations. Izotropic recently…

FridaySep 26, 2025 12:00 pm

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Anticipating Tomorrow’s Imaging Standards Today

CMS proposal keeps CT radiation quality measure voluntary, highlighting ongoing debate around dose safety and image quality Izotropic’s IzoView breast CT system engineered to deliver low-dose, high-resolution 3D imaging, aligning with future regulatory and clinical priorities Company launches new FAQ page to enhance transparency for investors, clinicians, and decision-makers In medical imaging, technology often races ahead of regulation. A recent proposal from the Centers for Medicare & Medicaid Services (CMS) underscores this tension: the agency is opting not to mandate radiation dose tracking for CT scans by 2027. While the decision reflects operational challenges hospitals face in meeting such requirements,…

ThursdaySep 25, 2025 9:10 am

QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights AI Role in Breast Imaging With New Feature Article

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) announced the publication of a feature article on BreastCT.com titled “AI Is Reshaping Breast Imaging, and IzoView Was Built for What Comes Next.” The piece underscores the limitations of legacy systems and details how the Company’s flagship IzoView Breast CT Imaging System was purpose-built for AI-driven imaging. Key points include global validation of AI’s role in improving cancer detection, IzoView’s proprietary 3D hardware and 10-second compression-free scans, and its positioning as a scalable, protected platform with a $500,000 target price designed to set a new standard in breast cancer screening. To view the…

TuesdaySep 23, 2025 10:30 am

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) CEO Featured in BMW Podcast Discussing Breakthrough Breast CT Imaging

“Screening is the first line of defense,” said IZO CEO Robert Thast, who noted that company’s Breast CT technology can detect cancers as small as two millimeters. Thast summarized Izotropic’s recent advances in artificial intelligence. Company’s commercialization plans start in Europe and then expand to U.S, with focus on selling primarily to hospitals, medical facilities and imaging clinics. A new episode of the BioMedWire Podcast shines a spotlight on Izotropic (CSE: IZO) (OTCQB: IZOZF) and its innovative approach to breast cancer imaging. Featuring IZO CEO Robert Thast, the podcast (ibn.fm/JUWtD) reveals how Izotropic’s proprietary Breast CT technology could transform early…

FridaySep 19, 2025 9:50 am

QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Closes $375,000 Private Placement

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based products for more accurate breast cancer screening, diagnosis and treatment, announced it has closed a non-brokered private placement of 1.5 million units at $0.25 per unit for gross proceeds of $375,000. Each unit includes one common share and one transferable warrant exercisable at $0.50 for three years. Proceeds will be used for general working capital. An insider acquired 100,000 units under exemptions from MI 61-101 requirements, and the company paid $3,500 and issued 14,000 broker warrants exercisable at $0.25 for three years in connection with the offering.…

TuesdaySep 16, 2025 9:50 am

QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches FAQ Page to Enhance Transparency and Investor Engagement

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the detection and treatment of breast cancer, has launched a new Frequently Asked Questions page on its corporate website at www.izocorp.com/faq. The resource provides accessible information on the company’s IzoView Breast CT Imaging System, development milestones, and competitive positioning, addressing topics such as breast density, imaging workflow, and comparisons with other modalities. Optimized for search and AI platforms, the FAQ page supports Izotropic’s investor relations, clinical outreach, and advocacy initiatives. To view the full press release, visit https://ibn.fm/I1kkE About Izotropic More information about Izotropic Corporation…

Site Search

Company Search

Tag: Izotropic Corp. IZOZF